<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-0WBYOH5X</identifier><date>2019</date><creator>Bratkovič, Tomaž</creator><relation>documents/doc/0/URN_NBN_SI_doc-0WBYOH5X_001.pdf</relation><relation>documents/doc/0/URN_NBN_SI_doc-0WBYOH5X_001.txt</relation><format format_type="issue">1</format><format format_type="volume">70</format><format format_type="type">article</format><format format_type="extent">str. 57-68</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID_HOST">4708209</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-0WBYOH5X</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">Bolezni</subject><subject language_type_id="slv">Duchennova mišična distrofija</subject><subject language_type_id="slv">Genetika</subject><subject language_type_id="slv">povezovanje eksonov</subject><subject language_type_id="slv">protismiselni oligonukleotidi</subject><subject language_type_id="slv">spinalna mišična atrofija</subject><title>Modulacija povezovanja eksonov s protismiselnimi oligonukleotidi kot terapevtska strategija</title><title>Splicing modulation with antisense oligonucleotides as a therapeutic strategy</title></Record>